| Productname |
 IGFBP-3 |
|
Insulin like Growth Factor Binding Protein- 3 |
| Cat-No. |
E03A |
| Range |
0.4 - 30 ng/ml |
| Sensitivity |
0.1 ng/ml |
| Incubation time |
2.5 hours RT |
| Sample volume |
10 µl (dilute 1:505 for serum and plasma) |
| Sample type |
Serum, plasma (heparin), CSF, cell culture. Results in citrate or EDTA plasma are about 15% reduced. |
| Sample preparation |
Samples have to be chilled as soon as possible after collection. Long-term storage should be carried out at –20°C or below. Maximum 5 freeze/thaw cycles. |
| Reference values |
In contrary to GH IGFBP-3 shows stable serum levels due to absence of circadian variation. In children IGFBP-3 levels are strongly age and gender dependent. A detailed table is included in the product brochure. |
| Species |
Human |
| Tests |
96 Tests |
| Method |
ELISA |
| Product informations |
- Cross-reaction all species (pdf-File 71 kb)
|
| Intended use |
IGFBP-3 is a peptide of 264 amino acids (MW 29kDa), forming a complex with a 150 kDa glycoprotein (ALS, acid labile subunit) and one molecule of IGF. In serum, approximately 95% of IGF-I and IGF-II are bound to IGFBP-3, making this protein to the main carrier of the circulating insulin-like growth factor. The function of the binding protein is to prolong the half-life of the circulating growth factor towards several hours. The determination of IGFBP-3 has been proposed as the best indicator of GHD during the five first years of life because of the low discrimination value of IGF-1 levels. A single IGFBP-3 determination is an excellent screening parameter for GHD and IGFBP-3 is a good parameter for monitoring the therapeutic efficacy in both GHD and acromegaly. |
Back to overview print view
